Skip to content
Case report Open access

Multidisciplinary treatment incorporating autologous DC-CIK cell therapy induces long-term survival in advanced pancreatic cancer: a case report

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 28 references
Medicine

TL;DR

These findings support multidisciplinary care as the cornerstone of long-term survival in liver cancer as an integral component of immunomodulation, DC-CIK cell therapy remodels the tumor microenvironment to facilitate other treatments, making it a defining therapeutic decision for patients with advanced liver cancer.

Abstract

Pancreatic cancer is widely acknowledged as one of the most aggressive malignancies of the digestive system. More than 80% of patients are diagnosed at an advanced stage with an extremely poor prognosis. While contemporary combination chemotherapy and the novel RAS inhibitor daraxonrasib have modestly prolonged survival, clinical benefits remain limited, necessitating less toxic yet more substantial and durable therapeutic strategies. Herein, we report a case of a patient with advanced metastatic adenocarcinoma who achieved disease stability and long-term survival following multidisciplinary treatment incorporating autologous DC-CIK cell therapy. The patient was a 73-year-old male diagnosed with poorly differentiated pancreatic ductal carcinoma 9 years ago. After surgery, he developed pelvic implantation metastases and subsequently received multi-line chemotherapy and radiotherapy. Thereafter, he completed five cycles of DC-CIK cell infusion at a dose of 5×109 ~10×109 cells between November 2018 and December 2019. The patient did not experience any obvious adverse reactions during the treatment. Post-treatment, the patient maintained a stable disease state. Although bone metastasis was detected in February 2021, the patient’s overall survival (OS) and progression-free survival (PFS) reached 107 and 49 months, respectively, far exceeding those previously reported in the literature. Furthermore, the patient experienced an improvement in quality of life. These findings support multidisciplinary care as the cornerstone of long-term survival in liver cancer. As an integral component of immunomodulation, DC-CIK cell therapy remodels the tumor microenvironment to facilitate other treatments, making it a defining therapeutic decision for patients with advanced liver cancer.

Read PDF

Similar papers

Case report Open access Sep 2026

Stage IIIB pulmonary sarcomatoid carcinoma treated with spatially fractionated radiotherapy combined with antiangiogenic therapy and sequential chemo-immunotherapy: A case report

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer, characterized by high invasiveness and treatment resistance. Patients with PSC often exhibit poor treatment outcomes, short median survival and a dismal prognosis, necessitating novel comprehensive treatment strategies to address thi...

Zi-Jian Qiu, F. Xuan, Xi-Lan Mao et al. · 0 citations
Case report Open access Oct 2026

Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma

Rationale: Renal cell carcinoma is a highly heterogeneous urological malignancy, with clear cell renal cell carcinoma (ccRCC) as the most common pathological subtype. A considerable proportion of patients are diagnosed at advanced stages or experience postoperative recurrence and distant metastasis, leading to poor lon...

Jing Zhang, Chun-Qiao Chen, Hui Huang et al. · 0 citations
Review Open access Aug 2026

Advances and future perspectives in the treatment of small cell lung cancer: From chemotherapy and radiotherapy to the era of targeted therapy and immunotherapy.

The progress in the treatment modalities for SCLC is focused on and future perspectives involving novel therapeutic combinations, assessment of new targets, and strategies to overcome treatment resistance are discussed.

Xiangwei Cheng, Weibin Lv, Linfeng Wu et al. · 0 citations
Case report Open access Oct 2026

Case Report: Low-dose radiotherapy as part of multimodal salvage therapy for immunotherapy-resistant SMARCA4-deficient non‐small cell lung cancer

SMARCA4-deficient non-small cell lung cancer (SD-NSCLC) is a highly aggressive molecular subtype. This malignancy is often diagnosed at an advanced stage, carrying a dismal prognosis and also demonstrating poor responsiveness to traditional treatment. Beyond its primary site, the disease can exhibit unusual metastatic...

T. Bu, Nan Zhang, T. Jin et al. · 0 citations
Open access Aug 2026

Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma

Introduction Soft tissue sarcomas (STS) are rare mesenchymal malignancies with limited treatment options in advanced stages. Anthracycline-based chemotherapy remains the standard of care but yields modest outcomes with significant toxicity, underscoring the need for more effective strategies. Methods We retrospectively...

Zhi-Chao Liao, Jun Huang, Hao-Tian Liu et al. · 0 citations
Case report Open access Aug 2026

Significant Intracranial Response and Long-term Survival after Pembrolizumab in Non-small Cell Lung Cancer Brain Metastases Resistant to Stereotactic Radiotherapy

Brain metastases from non-small cell lung cancer are typically managed with local therapies, such as surgery and radiotherapy, whereas systemic treatments have historically demonstrated limited efficacy in the intracranial setting. Immune checkpoint inhibitors, particularly programmed cell death-1 inhibitors, have rece...

Ryuichi Noda, A. Akabane, Mariko Kawashima et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.